company background image
VB0

Viva Biotech Holdings DB:VB0 Stock Report

Last Price

€0.18

Market Cap

€368.9m

7D

-9.8%

1Y

-72.5%

Updated

17 Sep, 2022

Data

Company Financials +
VB0 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health1/6
Dividends0/6

VB0 Stock Overview

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.

Viva Biotech Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Viva Biotech Holdings
Historical stock prices
Current Share PriceHK$0.18
52 Week HighHK$0.68
52 Week LowHK$0.18
Beta0.86
1 Month Change-21.37%
3 Month Change-39.07%
1 Year Change-72.54%
3 Year Changen/a
5 Year Changen/a
Change since IPO-64.14%

Recent News & Updates

Shareholder Returns

VB0DE Life SciencesDE Market
7D-9.8%-8.8%-3.4%
1Y-72.5%-41.8%-25.5%

Return vs Industry: VB0 underperformed the German Life Sciences industry which returned -41.9% over the past year.

Return vs Market: VB0 underperformed the German Market which returned -25.4% over the past year.

Price Volatility

Is VB0's price volatile compared to industry and market?
VB0 volatility
VB0 Average Weekly Movement6.8%
Life Sciences Industry Average Movement7.3%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: VB0 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: VB0's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20082,309Chen Cheney Maohttps://www.vivabiotech.com.cn

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins.

Viva Biotech Holdings Fundamentals Summary

How do Viva Biotech Holdings's earnings and revenue compare to its market cap?
VB0 fundamental statistics
Market Cap€368.90m
Earnings (TTM)€15.89m
Revenue (TTM)€312.06m

23.2x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VB0 income statement (TTM)
RevenueCN¥2.19b
Cost of RevenueCN¥1.51b
Gross ProfitCN¥679.68m
Other ExpensesCN¥568.35m
EarningsCN¥111.33m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.058
Gross Margin31.09%
Net Profit Margin5.09%
Debt/Equity Ratio70.7%

How did VB0 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VB0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VB0?

Other financial metrics that can be useful for relative valuation.

VB0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA13.8x
PEG Ratio0.4x

Price to Earnings Ratio vs Peers

How does VB0's PE Ratio compare to its peers?

VB0 PE Ratio vs Peers
The above table shows the PE ratio for VB0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.6x
GXI Gerresheimer
18.7x21.7%€1.5b
SLV Selvita
89.7x34.6%zł1.5b
PSG PharmaSGP Holding
26.1x13.3%€291.6m
MDG1 Medigene
6xn/a€57.7m
VB0 Viva Biotech Holdings
23.2x61.1%€2.9b

Price-To-Earnings vs Peers: VB0 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the peer average (45.6x).


Price to Earnings Ratio vs Industry

How does VB0's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Earnings vs Industry: VB0 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the European Life Sciences industry average (40.8x)


Price to Earnings Ratio vs Fair Ratio

What is VB0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VB0 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.2x
Fair PE Ratio50.3x

Price-To-Earnings vs Fair Ratio: VB0 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the estimated Fair Price-To-Earnings Ratio (50.3x).


Share Price vs Fair Value

What is the Fair Price of VB0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VB0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VB0's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Viva Biotech Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


61.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VB0's forecast earnings growth (61.1% per year) is above the savings rate (-0.01%).

Earnings vs Market: VB0's earnings (61.1% per year) are forecast to grow faster than the German market (9.8% per year).

High Growth Earnings: VB0's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VB0's revenue (32.7% per year) is forecast to grow faster than the German market (3.8% per year).

High Growth Revenue: VB0's revenue (32.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VB0's Return on Equity is forecast to be low in 3 years time (10.9%).


Discover growth companies

Past Performance

How has Viva Biotech Holdings performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


8.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VB0 has high quality earnings.

Growing Profit Margin: VB0's current net profit margins (5.1%) are lower than last year (15%).


Past Earnings Growth Analysis

Earnings Trend: VB0's earnings have grown by 8.1% per year over the past 5 years.

Accelerating Growth: VB0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VB0 had negative earnings growth (-51.3%) over the past year, making it difficult to compare to the Life Sciences industry average (26.3%).


Return on Equity

High ROE: VB0's Return on Equity (3%) is considered low.


Discover strong past performing companies

Financial Health

How is Viva Biotech Holdings's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: VB0's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥1.1B).

Long Term Liabilities: VB0's short term assets (CN¥2.0B) do not cover its long term liabilities (CN¥3.1B).


Debt to Equity History and Analysis

Debt Level: VB0's net debt to equity ratio (52.6%) is considered high.

Reducing Debt: VB0's debt to equity ratio has increased from 3.7% to 70.7% over the past 5 years.

Debt Coverage: VB0's debt is not well covered by operating cash flow (5.5%).

Interest Coverage: VB0's interest payments on its debt are not well covered by EBIT (1.3x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Viva Biotech Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VB0's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VB0's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VB0's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VB0's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: VB0 is not paying a notable dividend for the German market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VB0 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Chen Cheney Mao (60 yo)

4.17yrs

Tenure

Dr. Chen Cheney Mao, Ph D has been Chairman and Chief Executive Officer of Viva Biotech Holdings since July 03, 2018. He Founded Viva Biotech Holdings.Dr. Mao is the Chairman and Executive Director of Viv...


Leadership Team

Experienced Management: VB0's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: VB0's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

DB:VB0 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Sep 22Buy€2,182,966JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany10,521,208€0.21
05 Sep 22Buy€27,731JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany126,000€0.22
02 Sep 22Sell€2,373,961JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany10,354,208€0.23
30 Aug 22Buy€17,093JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany75,500€0.23
24 Aug 22Sell€431,883JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,858,969€0.23
15 Aug 22Buy€124,349JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany474,799€0.26
12 Aug 22Sell€117,729JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany447,799€0.26
11 Aug 22Buy€294,406JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,124,833€0.26
04 Aug 22Sell€1,632,715JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany6,402,424€0.26
28 Jul 22Sell€6,183,023JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany22,196,274€0.28
26 Jul 22Buy€5,310,611JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany18,937,702€0.28
30 May 22Buy€8,218,182JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany30,003,500€0.27
25 May 22Sell€8,514,294JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany30,542,994€0.28
24 May 22Sell€2,985,782JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany10,530,458€0.28
23 May 22Buy€3,191,018JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany10,375,458€0.31
17 May 22Sell€191,453JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany706,270€0.27
13 May 22Buy€594,265JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany2,167,770€0.27
05 May 22Buy€1,951,942JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany6,764,424€0.29
25 Apr 22Buy€1,644,225JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany5,689,560€0.29
21 Mar 22Sell€2,335,206JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany6,649,424€0.35
17 Mar 22Buy€2,608,560JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany7,868,151€0.33
09 Mar 22Sell€283,491JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany958,000€0.30
24 Feb 22Buy€2,014,975JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany5,765,000€0.35
27 Jan 22Sell€347,277Mao Investment TrustCompany811,500€0.43
26 Jan 22Sell€3,932,950JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany8,508,523€0.46
24 Jan 22Buy€2,874,623JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany6,009,069€0.48
21 Jan 22Sell€187,353JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany331,500€0.57
20 Jan 22Buy€164,033JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany359,000€0.46
12 Jan 22Buy€674,729JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,327,500€0.51
28 Dec 21Buy€5,247,334Zhang and Sons LimitedCompany10,000,000€0.52
28 Dec 21Sell€5,247,714Chen Cheney MaoIndividual10,000,000€0.52
23 Dec 21Sell€6,294JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany12,000€0.52
23 Dec 21Sell€6,229,697JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany11,877,065€0.52
21 Dec 21Buy€6,497JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany12,000€0.54
21 Dec 21Sell€9,845,703JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany18,184,418€0.54
20 Dec 21Buy€10,465,553JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany19,245,418€0.54
15 Dec 21Buy€7,674,675JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany13,722,065€0.56
08 Dec 21Sell€844,187UBS Asset ManagementCompany1,390,000€0.61
07 Dec 21Sell€7,720,355JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany12,577,565€0.61
30 Nov 21Sell€6,984,077JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany13,084,418€0.53
26 Nov 21Buy€9,444,639JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany16,717,254€0.56
24 Nov 21Sell€10,401,700JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany18,775,039€0.55
23 Nov 21Buy€11,600,128JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany20,931,807€0.55
17 Nov 21Buy€12,968,914JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany21,532,213€0.60
12 Nov 21Sell€6,908,793JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany12,040,064€0.57
11 Nov 21Buy€6,773,189JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany12,000,564€0.56
05 Nov 21Sell€13,361,398JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany24,279,517€0.55
03 Nov 21Buy€6,974,644JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany13,736,000€0.51
03 Nov 21Sell€8,185,032Chen Cheney MaoIndividual15,000,000€0.55
01 Nov 21Buy€1,051,051Zhang and Sons LimitedCompany15,000,000€0.07
28 Oct 21Buy€7,091,583JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany11,043,081€0.64
04 Oct 21Buy€134,853Ying WuIndividual210,000€0.64
30 Sep 21Buy€69,137Ying WuIndividual107,500€0.64
29 Sep 21Buy€124,880Ying WuIndividual200,000€0.62

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 55.18% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.76%
Jiong Wu
224,444,544CN¥41.3m0%no data
10.01%
Chen Cheney Mao
191,118,527CN¥35.2m34.82%no data
7.86%
Mao Investment Trust
150,000,000CN¥27.6m-15.56%no data
6.07%
Min Zhou
115,925,000CN¥21.3m0%no data
3.49%
Zhang and Sons Limited
66,577,225CN¥12.3m-59.4%no data
2.9%
Jun Mao
55,299,959CN¥10.2m0%no data
2.41%
Invesco Great Wall Fund Management Co. Ltd
46,000,000CN¥8.5m0%0.04%
2.24%
UBS Asset Management
42,730,574CN¥7.9m0%no data
1.2%
The Vanguard Group, Inc.
22,825,000CN¥4.2m-11.17%no data
0.99%
Ying Wu
18,937,473CN¥3.5m0%no data
0.81%
GF Fund Management Co., Ltd.
15,385,500CN¥2.8m0%0.01%
0.78%
Delin Ren
14,820,248CN¥2.7m0%no data
0.75%
BlackRock, Inc.
14,408,500CN¥2.7m-0.48%no data
0.63%
China Universal Asset Management Company Ltd.
12,064,000CN¥2.2m0%0.01%
0.55%
JPMorgan Chase & Co, Brokerage and Securities Investments
10,502,714CN¥1.9m-77.85%no data
0.47%
Franklin Resources, Inc.
8,997,000CN¥1.7m0%no data
0.35%
Lombarda China Fund Management Co., Ltd.
6,722,500CN¥1.2m0%no data
0.35%
Bosera Asset Management Co., Ltd.
6,613,500CN¥1.2m670.36%0.01%
0.34%
Vvbi Limited
6,529,246CN¥1.2m0%no data
0.29%
Harvest Fund Management Co., Ltd.
5,631,000CN¥1.0m0%no data
0.23%
Huixin Zhao
4,324,654CN¥795.7k0%no data
0.22%
Norges Bank Investment Management
4,209,256CN¥774.5k0%no data
0.19%
Fenghe Canary Limited
3,689,548CN¥678.9k0%no data
0.16%
Dimensional Fund Advisors LP
2,969,449CN¥546.4k200.07%no data
0.15%
Broad Asset Management Co., Ltd
2,820,000CN¥518.9k0%0.03%

Company Information

Viva Biotech Holdings's employee growth, exchange listings and data sources


Key Information

  • Name: Viva Biotech Holdings
  • Ticker: VB0
  • Exchange: DB
  • Founded: 2008
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$2.902b
  • Listing Market Cap: HK$368.900m
  • Shares outstanding: 1.91b
  • Website: https://www.vivabiotech.com.cn

Number of Employees


Location

  • Viva Biotech Holdings
  • No.735, Ziping Road
  • Zhoupu Town
  • Shanghai
  • 201318
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1873SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDMay 2019
VB0DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2019
VBIZ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/17 00:00
End of Day Share Price2022/09/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.